Summary: Prediabetes, according to the definition of the Polish Diabetes Society (PTD), is impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT). According to the American Diabetes Association (ADA) criteria, prediabetes is also diagnosed when the HbA1c rate is 5.7-6.4%. Prediabetes in the world affects about 7.3% of the adult population aged 20-79, i.e. about 352.1 million people, about 2.5 million in Poland, and its prevalence is still growing. The annual risk of developing diabetes in a patient diagnosed with IFG or IGT is significantly higher than in a person without these disorders, especially in the case when both coexist. Thus, the diagnosis of prediabetes is an indication for interventions aimed at preventing the development of diabetes. Lifestyle modification (appropriate diet and increased physical activity) remains the basis of prediabetes treatment and is more effective than pharmacotherapy with metformin. It is recommended to use a diet similar to diabetic, reduction diet in the case of coexisting overweight or obesity. Other types of diets, including the ketogenic diet, have no proven long-term benefits. The recommended types of exercise for patients with prediabetes are aerobic training or a combination of aerobic and resistance training for at least 150 minutes per week. The basis of pharmacotherapy in prediabetes is metformin, the only drug registered for this indication. New groups of antidiabetic drugs – SGLT2 inhibitors and GLP-1 analogues are currently possible to be used in the presence of other indications, while in relation to the use in prediabetes alone, they require further research.